All Substitutes
Loading...
Disclaimer
Did you find this information helpful?
Afzeta 40mg Tablet
Prescription Required
Salt Composition : Afatinib Dimaleate
Manufacturer : SUN PHARMACEUTICAL INDUSTRIES LTD
Origin of Medicine : India
30 Tablet(s) In A Bottle
Get financial assistance directly from pharma companies and cover your cost of medicines or get free medicines for the eligible patient with patient assistance programs (PAP). We provide proper guidance assistance to patients getting enrolled in the patient assistance program.
Introduction to Afzeta 40mg Tablet
Afzeta 40mg Tablet is an anticancer medicine containing Afatinib dimaleate as an active ingredient. It is used to treat patients with non-small cell lung cancer (NSCLC) whose tumors have certain (non-resistant) abnormal epidermal growth factor receptor (EGFR) genes and patients with metastatic, squamous NSCLC progressing after platinum-based chemotherapy. Cancer is a disorder in which cells multiply in an abnormal and uncontrolled manner. Talk to your doctor if you have kidney disorders, breathing problems, liver disorders, heart problems, intolerance to sugars, severe dry eye, or other eye problems before taking this medicine.
Afzeta 40mg Tablet can delay disease progression and improve overall survival, it can also help patients maintain a better quality of life for a longer period of time. This includes improved physical functioning, reduced pain, and better mental and emotional health. Tell your doctor if you are wearing contact lenses or breastfeeding before taking this medication. Limit your time in the sun as this medicine may make your skin sensitive to the sun. It is not recommended for children and adolescents under the age of 18. Do not stop taking this medicine without consulting your doctor.
Uses of Afzeta 40mg Tablet
Afzeta 40mg Tablet is indicated to treat the following conditions:
- Non-small cell lung cancer (NSCLC)
Therapeutic Effects of Afzeta 40mg Tablet
The therapeutic effect of Afzeta 40mg Tablet is primarily related to its ability to inhibit the activity of certain proteins in cancer cells, specifically the epidermal growth factor receptor (EGFR) family of proteins. These proteins play a key role in promoting the growth and spread of cancer cells, and by inhibiting their activity, it can help to slow or stop the progression of cancer.
Interaction of Afzeta 40mg Tablet with other drugs
The therapeutic effect of Afzeta 40mg Tablet is primarily related to its ability to inhibit the activity of certain proteins in cancer cells, specifically the epidermal growth factor receptor (EGFR) family of proteins. These proteins play a key role in promoting the growth and spread of cancer cells, and by inhibiting their activity, it can help to slow or stop the progression of cancer.
More Information about Afzeta 40mg Tablet
- Afzeta 40mg Tablet should be stored at room temperature, between 20°C to 25°C (68°F to 77°F).
- Protected from light.
- Keep it in its original packaging until it is ready to be used.
- Keep out of the reach of children and pets.
- Should be disposed of properly.
How to consume Afzeta 40mg Tablet
Afzeta 40mg Tablet is an oral medication that is usually taken once a day, at approximately the same time each day, with or without food. It should be taken as prescribed by a doctor. These capsules should be swallowed whole with a glass of water. They should not be crushed, chewed, or opened, as this can affect how the medication is absorbed and decrease its effectiveness. You should not take a double dose to make up for the second dose.
Safety Advices for Afzeta 40mg Tablet
Pregnancy
Afzeta 40mg Tablet is unsafe during pregnancy as it can cause fetal harm. It is recommended to avoid this medication during pregnancy.
Breast Feeding
It is unknown, whether Afzeta 40mg Tablet is excreted in human milk or not, and the potential risks to a nursing infant are unknown. So nursing women should consult a healthcare provider before taking it.
Lungs
Afzeta 40mg Tablet is primarily used to treat non-small cell lung cancer (NSCLC). Patients should consult healthcare providers if they have any other lung disease before taking it.
Liver
Afzeta 40mg Tablet is primarily metabolized in the liver, so inform your healthcare provider if you have any liver problems or diseases. This medication may also increase liver enzymes, which can be a sign of liver damage or inflammation. Patients taking this medication require regular blood tests to monitor liver function.
Alcohol
It is recommended to avoid consuming alcohol while taking Afzeta 40mg Tablet, as alcohol can increase the risk of certain side effects associated with the medication, such as stomach ulcers or gastrointestinal bleeding.
Driving
Patients receiving Afzeta 40mg Tablet should be advised to avoid driving or operating machinery if they experience side effects such as fatigue, dizziness, or blurred vision, impairing a patient's ability to drive or operate machinery safely.
Side Effects of Afzeta 40mg Tablet
Like all medications, Afzeta 40mg Tablet can cause side effects, although not everyone who takes it will experience them.
Serious:
- Interstitial lung disease (ILD)
- Severe diarrhea or dehydration
- Liver problems
- Eye problems, such as corneal erosion or ulceration
- Hemorrhage or bleeding problems
- Kidney problems
- Cardiac problems
Common:
- Diarrhea
- Mouth sores
- Acne or skin rash
- Nausea and vomiting
- Fatigue
- Loss of appetite
- Abdominal pain
- Nail changes, such as nail bed infections or inflammation
- Dry skin or itching
- Eye irritation or dryness
- Respiratory infections
Word of Advice
Follow all instructions and dosing recommendations provided by your healthcare provider. Do not take more or less of the medication than prescribed. Report any new or worsening symptoms to your healthcare provider immediately, especially if they relate to your lungs, eyes, skin, liver, kidneys, heart, or bleeding. Stay well-hydrated and report any signs or symptoms of dehydration to your healthcare provider immediately, especially if you experience severe diarrhea. Women should avoid pregnancy or breastfeeding. Reproductive-age women should use effective birth control during the treatment and for at least two weeks after your last dose. Patients should report any signs or symptoms of dehydration, such as dry mouth or decreased urination, to a healthcare provider immediately.
FAQs
Q 1. Can I donate blood while taking Afzeta 40mg Tablet?
Patients should not donate blood while taking Afzeta 40mg Tablet, as the medication can be harmful to the recipient. It is important to inform your healthcare provider if you plan to donate blood, as they may advise you to wait until after you have finished treatment.
Q 2. Can I continue to work or go to school while taking Afzeta 40mg Tablet?
The ability to work or go to school while taking Afzeta 40mg Tablet will depend on your individual condition and response to treatment. Some patients may experience fatigue or other side effects that can impact their ability to perform daily activities.
Q 3. Does Afzeta 40mg Tablet have any effect on fertility?
There is limited information on the effects of Afzeta 40mg Tablet on fertility. However, it is important to inform your healthcare provider if you are trying to conceive, as some cancer treatments can affect fertility.
Q 4. Can I take Afzeta 40mg Tablet if I have a history of heart problems?
If you have a history of heart problems, it is important to discuss the potential risks and benefits of using Afzeta 40mg Tablet with your healthcare provider before starting treatment. This medication can cause cardiac problems, and your healthcare provider may need to monitor you closely during treatment.
Q 5. Can Afzeta 40mg Tablet be used in combination with other cancer treatments?
Afzeta 40mg Tablet is sometimes used in combination with other cancer treatments, such as chemotherapy or immunotherapy. However, the safety and effectiveness of these combinations will depend on your individual condition and treatment plan.
Fact Box of Afzeta 40mg Tablet
Molecule name: Afatinib dimaleate | Therapeutic class: Anticancer |
Pharmacological class: Tyrosine kinase inhibitor | Indications: Non-small cell lung cancer (NSCLC) |
References
- Boehringer Ingelheim Pharmaceuticals, Inc, US Food and Drug Administration, [ Revised on Jan 2018] [ Accessed on 21st April 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/4018/401292s014lbl.pdf
- Boehringer Ingelheim International GmbH, Electronic medicines compendium (EMC), [ Revised on Sept 2020] [ Accessed on 21st April 2023], https://www.medicines.org.uk/emc/files/pil.5147.pdf
- Helga Wecker, Cornelius F Waller; Afatinib; Recent Results in Cancer Research 2018; https://pubmed.ncbi.nlm.nih.gov/40069769/
Disclaimer
MrMed’s primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on MrMed. Our mission is to support, not replace, the doctor-patient relationship.
